Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

J-P Lacour1

  • 1Service de dermatologie, Hôpital Archet 2, CHU de Nice, CS 23079 06202, Nice, Cedex 3, France.

Annales De Dermatologie Et De Venereologie
|November 30, 2020
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of radiotherapy schedule on survival of patients treated with immune-checkpoint inhibitors for advanced melanoma and non-small cell lung cancer.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2022
Same author

Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same author

Leg ulcers in childhood: A multicenter study in France.

Annales de dermatologie et de venereologie·2021
Same author

Successful treatment of recalcitrant genital lichen planus with secukinumab.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021
Same author

Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).

The British journal of dermatology·2020
Same author

Secukinumab efficacy in reducing the severity and the psychosocial impact of moderate-to-severe psoriasis as assessed by the Simplified Psoriasis Index: results from the IPSI-PSO study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2020
Same journal

2024 guidelines (S3) for the therapeutic management of patients with genital herpes.

Annales de dermatologie et de venereologie·2026
Same journal

Topical JAK inhibitors in the lichen planus spectrum: a systematic review.

Annales de dermatologie et de venereologie·2026
Same journal

2024 recommendations for the therapeutic management of anogenital warts.

Annales de dermatologie et de venereologie·2026
Same journal

Successful use of thalidomide in treating metastatic Crohn's disease.

Annales de dermatologie et de venereologie·2026
Same journal

Multiple cutaneous juvenile xanthogranuloma: a monocentric study.

Annales de dermatologie et de venereologie·2026
Same journal

Cartilage-hair-hypoplasia associated with granulomatosis induced by rubella vaccine.

Annales de dermatologie et de venereologie·2026
See all related articles

Atopic dermatitis severity scores are increasingly vital for tracking eczema treatment effectiveness. Standardization efforts, like the Harmonizing Outcome Measures for Eczema (HOME) initiative, are simplifying objective assessment and patient-reported outcomes.

Area of Science:

  • Dermatology
  • Clinical Trials
  • Outcome Measurement

Background:

  • Atopic dermatitis (eczema) severity assessment tools are less established in clinical practice compared to psoriasis.
  • Therapeutic advancements in eczema necessitate objective measures for disease severity and treatment response.

Purpose of the Study:

  • To review and detail the most commonly used severity assessment scores for atopic dermatitis.
  • To highlight the trend towards simplification and standardization of eczema outcome measures.

Main Methods:

  • Review of existing literature on atopic dermatitis severity scores.
  • Focus on scores validated and recommended by initiatives such as the Harmonizing Outcome Measures for Eczema (HOME) group.

Main Results:

Keywords:
Atopic dermatitisAtopic eczemaDermatite atopiqueEASIEczéma atopiqueIGAPOEMSCORADScoresScoring

Related Experiment Videos

  • A shift from numerous, poorly validated scores to a trend of simplification and standardization.
  • Identification of a core outcome set including objective clinical signs, patient-reported symptoms, quality of life, and long-term disease control.

Conclusions:

  • Standardized eczema assessment scores are crucial for evaluating new therapies and clinical practice.
  • The Harmonizing Outcome Measures for Eczema (HOME) group's work is central to establishing a core outcome set for atopic dermatitis.